Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 9573
LigandPNGBDBM50149477(CHEMBL3770993 | US8242104, Compound 375 | US108510...)
Affinity DataKi:  0.0160nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295675(US8242104, Compound 469 | US10851091, U.S. Pat. No...)
Affinity DataKi: <0.0200nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295679(US8242104, Compound 529 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.0230nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  0.0340nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295670(US10112932, Compound 106 | (S)-2-((2-((S)-4-(fluor...)
Affinity DataKi:  0.0400nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295671(US10112932, Compound 107 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  0.0480nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295669(US10112932, Compound 105 | (S)-2-cyclopropyl-2-((2...)
Affinity DataKi:  0.0510nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  0.0600nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  0.0790nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  0.0900nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  0.0900nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295686(US8242104, Compound 550 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.107nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295676(US8242104, Compound 486 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.186nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50149548(CHEMBL3771364 | US8242104, Compound 436 | US108510...)
Affinity DataKi:  0.350nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295675(US8242104, Compound 469 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.390nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50149477(CHEMBL3770993 | US8242104, Compound 375 | US108510...)
Affinity DataKi:  0.417nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295684(US8242104, Compound 544 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.437nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295668(US10112932, Compound 104 | (S)-2-cyclopropyl-2-((2...)
Affinity DataKi:  0.464nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475621(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  0.560nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295687(US8242104, Compound 356 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.920nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295666(US10112932, Compound 102 | (S)-2-cyclobutyl-2-((2-...)
Affinity DataKi:  0.949nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295687(US8242104, Compound 356 | US10851091, U.S. Pat. No...)
Affinity DataKi:  0.967nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295679(US8242104, Compound 529 | US10851091, U.S. Pat. No...)
Affinity DataKi:  1.05nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  1.43nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM25028(4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpipera...)
Affinity DataKi:  1.54nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475622(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  1.70nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295686(US8242104, Compound 550 | US10851091, U.S. Pat. No...)
Affinity DataKi:  1.96nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295676(US8242104, Compound 486 | US10851091, U.S. Pat. No...)
Affinity DataKi:  2.5nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM25028(4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpipera...)
Affinity DataKi:  2.56nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295682(US8242104, Compound 540 | US10851091, U.S. Pat. No...)
Affinity DataKi:  2.72nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295677(US8242104, Compound 501 | US10851091, U.S. Pat. No...)
Affinity DataKi:  3.56nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475622(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  5.66nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50149548(CHEMBL3771364 | US8242104, Compound 436 | US108510...)
Affinity DataKi:  6.94nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475621(US10851091, U.S. Pat. No. 8,242,104 No. 549 isomer...)
Affinity DataKi:  9.41nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295684(US8242104, Compound 544 | US10851091, U.S. Pat. No...)
Affinity DataKi:  11.3nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  12.2nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295670(US10112932, Compound 106 | (S)-2-((2-((S)-4-(fluor...)
Affinity DataKi:  16.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295671(US10112932, Compound 107 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  17.5nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295670(US10112932, Compound 106 | (S)-2-((2-((S)-4-(fluor...)
Affinity DataKi:  17.8nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295665(US10112932, Compound 101 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  18.2nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295677(US8242104, Compound 501 | US10851091, U.S. Pat. No...)
Affinity DataKi:  21.8nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295671(US10112932, Compound 107 | (S)-2-((2-((S)-4-(diflu...)
Affinity DataKi:  23.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295682(US8242104, Compound 540 | US10851091, U.S. Pat. No...)
Affinity DataKi:  24.1nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295669(US10112932, Compound 105 | (S)-2-cyclopropyl-2-((2...)
Affinity DataKi:  30.3nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM295669(US10112932, Compound 105 | (S)-2-cyclopropyl-2-((2...)
Affinity DataKi:  36.4nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  37.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM25028(4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpipera...)
Affinity DataKi:  41.8nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM475607(US10851091, Compound 103)
Affinity DataKi:  49nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

LigandPNGBDBM50434806(CHEMBL2387080 | Taselisib | GDC 0032 | 2-(4-(2-(1-...)
Affinity DataKi:  53nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/12/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: